Markers for efficacy of mammalian target of rapamycin inhibitor

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Mammalian target of rapamycin (mTOR) is a key regulator of cell growth, metabolism, and translation.
• mTOR signaling is frequently dysregulated in various cancers, contributing to tumorigenesis.
• Clinical use of mTOR inhibitors (rapalogs) shows variable patient responses, necessitating predictive biomarkers.

Purpose of the Study:

• To review cellular mechanisms and clinical findings related to mTOR inhibitors.
• To identify and discuss potential biomarkers for predicting mTOR inhibitor efficacy.
• To guide the selection of optimal biomarkers for personalized cancer therapy.

Main Methods:

• Literature review of cellular mechanisms governing mTOR signaling.
• Analysis of clinical study outcomes for mTOR inhibitors.
• Evaluation of potential biomarker categories: candidate selection, baseline expression, pathway inhibition, and protein source.

Main Results:

• Rapalogs demonstrate antitumor activity, but response rates are modest on average.
• A subset of patients experiences significant clinical benefits from mTOR inhibitors.
• Several factors, including baseline expression and pathway inhibition, are being investigated as predictive markers.

Conclusions:

• Understanding mTOR pathway biology and clinical data is essential for biomarker discovery.
• Biomarkers are needed to stratify patients and optimize the use of mTOR inhibitors.
• Further research into candidate selection, expression levels, and protein targets will refine predictive models.